Chagas disease is a neglected tropical disease that reaches millions of people, especially in Latin America, where it is endemic. According to the World Health Organization (WHO) and the Drugs for Neglected Diseases Initiative (DNDi), Chagas disease occupies a position of high priority in their programs of research and development of new drugs. The available drugs are extremely limited and insufficient, characterized by low efficacy and high toxicity. In this context, the development of new, more effective and safe medicines is of paramount importance.The main goals of this project are the development and evaluation of new drug candidates for Chagas disease. The project is of utmost importance for the Center for Research and Innovation in Biodiversity and Drug Discovery (CIBFar, one of the CEPIDs supported by FAPESP), which has solid partnerships with UNICAMP and DNDi in order to develop drug candidates for neglected diseases such as leishmaniasis and Chagas disease. The project comprises methods of ligand-based drug design (LBDD); organic synthesis; in vitro biological evaluation against the parasite Trypanosoma cruzi and assays on culture of human cells to evaluate the selectivity of the compounds. Computational and experimental methods will be integrated in the process of molecular optimization of the compounds. The project will be developed in the Laboratory of Medicinal and Computational Chemistry (LQMC), at the Physics Institute of São Carlos (IFSC-USP) - the host institution of the CIBFar-CEPID/FAPESP.
News published in Agência FAPESP Newsletter about the scholarship: